Mitsubishi Tanabe Pharma (MTP-CA) Receives Health Canada Approval of Radicava for Amyotrophic Lateral Sclerosis (ALS)
Shots:
- The Notice of Compliance (NOC) authorization is based on the clinical trial assessing Radicava (edaravone)- demonstrating its positive 1EP measured by using the ALSFRS-R
- Edaravone is a IV medication- received the US FDA PR designation to treat ALS and marketed as Radicava in the US and as Radicut in Japan (IV 30mg) to treat acute stage of cerebral infection
- In Mar-2018 Mitsubishi Tanabe Pharma America’s (MTPA) subsidiary MTP-CA will process the distribution of RADICAVA in Canada. ALS is idiopathic neurodegenerative disorder with ~2 in 100-000 are affected globaly & and as reported by ALS Society of Canada almost 3-000 Canadians are living with ALS
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
